JPMorgan analyst Chris Schott upgraded Amneal Pharmaceuticals (NASDAQ: AMRX) from Underweight to Neutral with a price target of $9.00.The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE